undefined
EUTM file information

018888980

ACEPODIA


June 14, 2023

Trademark Summary

The trademark application ACEPODIA was filed by Acepodia Biotechnologies Ltd, a corporation established under the laws of Taiwan, Republic of China (the "Applicant"). The application was published for oppositions on September 5, 2023, and it was registered by office on December 13, 2023 without any oppositions.

The application was filed in English (German was selected as the second language).

Change of name and professional address of the trademark registration was recorded on January 17, 2024.


Goods And Services

  • The mark was filed in class 5 with following description of goods:
    1. Biological preparations for medical or therapeutic purposes
    2. Biological tissue cultures for medical purposes
    3. Medicines for human purposes
    4. Drugs for medical purposes
    5. Pharmaceuticals
    6. Cells for clinical, medical, veterinary, or therapeutic purposes or use
    7. Cell-derived preparations, namely, natural killer cell, gamma delta T cell, or other immune cell-derived preparations, for clinical, medical, veterinary, or therapeutic purposes
    8. Therapeutic products derived from cells or cell-derived preparations, namely, natural killer cells, gamma delta T cell, or other immune cell, for clinical, medical, veterinary, or therapeutic purposes
    9. Kits comprised of cells, reagents and related instructions, for clinical, medicinal, veterinary, or therapeutic purposes or use
    10. Kits comprised of cell-derived preparations, namely, natural killer cell, gamma delta T cell, or other immune cell-derived preparations, reagents and related instructions, for clinical, medicinal, veterinary, or therapeutic purposes or use
    11. Gene therapy products, namely, genetically engineered cells for medical or clinical purposes or use
    12. Pharmaceutical preparations, pharmaceutical products, therapeutic agents, or drugs, for targeting tissues based on select tissue markers and ligands, or for the purpose of binding ligands using engineered proteins and receptors
    13. Pharmaceuticals, namely, pharmaceutical preparations, pharmaceutical products, therapeutic agents, or drugs, for use in the prevention and treatment of cancer, tumors, hematologic disease, solid cancers, hyperproliferative disease, autoimmune disease, neuronal diseases, hematopoietic cell-related diseases, metabolic syndrome, infectious diseases, immune disease or disorder, and other diseases or disorders, and in cellular transplants
    14. Biotechnology and pharmaceutical products, namely, therapeutic cells, therapeutic peptide, therapeutic proteins, and therapeutic nucleic acids for human use for the treatment and prevention of cancer, tumors, autoimmune disease, a neuronal disease, a hematopoietic cell-related disease, metabolic syndrome, infectious diseases, immune disease, inflammation and inflammatory diseases
    15. Pharmaceutical preparations or pharmaceutical products, namely, cell media for use in activating t-cells for use in adoptive t-cell therapy for the treatment of hematological and solid cancers
    16. Pharmaceutical preparations, biological preparations, or therapeutic agents to modulate cell function or cell fate
    17. Reagents for pre-clinical, clinical, and medical use
    18. Biological preparations or therapeutic agents used for medical cell therapy, adoptive immunotherapy, or other immunotherapy
    19. Therapeutic cell preparation based on NK cells (natural killer cells), gamma delta T cell, other immune cell, or other cell for the treatment of cancer, tumors, neuronal diseases, hematopoietic cell-related diseases, metabolic syndrome, infectious diseases, auto-immune diseases, and inflammatory and immune disorders
    20. Preparation of bio-engineered components for a therapeutic material, namely, cell lines based on NK cells (natural killer cells), gamma delta T cell, or other immune cell used for medical or clinical use used for immunotherapy.